Abstract:Although there is recent evidence that cells from the peripheral immune system can gain access to the central nervous system in certain conditions such as multiple sclerosis, their role has not been assessed in psychosis. Here, we aimed to explore whether blood cell count was associated with brain volume and/or clinical symptomatology. A total of 218 participants (137 first-episode psychosis patients [FEP] and 81 healthy controls [HC]) were included in the study. For each participant, a T1 structural image was… Show more
“…Of note, because we can only derive proportion of cell types from whole blood DNA methylation data, and not actual counts, an increase in one or more cell types must be balanced by a decrease in one or more other cell types and an apparrent change in the proportion of one specific cell type does not mean that the actual abundance of that cell type is altered. Despite this, the results from DNA methylation-derived cell proportions are consistent with previous studies based on empirical cell abundance measures which have reported increased monocyte counts 67,68 , increased neutrophil counts 69,70 , increased monocyte to lymphocyte ratio 71,72 and increased neutrophil to lymphocyte ratio 71,73 in both schizophrenia and FEP patients compared to controls. Studies have also shown that higher neutrophil counts in schizophrenia patients correlate with a greater burden of positive symptoms 69 suggesting that variations in the number of neutrophils is a potential marker of disease severity 72 .…”
Section: Discussionsupporting
confidence: 88%
“…Despite this, the results from DNA methylation-derived cell proportions are consistent with previous studies based on empirical cell abundance measures which have reported increased monocyte counts 67,68 , increased neutrophil counts 69,70 , increased monocyte to lymphocyte ratio 71,72 and increased neutrophil to lymphocyte ratio 71,73 in both schizophrenia and FEP patients compared to controls. Studies have also shown that higher neutrophil counts in schizophrenia patients correlate with a greater burden of positive symptoms 69 suggesting that variations in the number of neutrophils is a potential marker of disease severity 72 . Our sub-analysis of treatment-resistant schizophrenia, which is associated with a higher number of positive symptoms 65 , found that the increase in granulocytes was primary driven by those with the more severe phenotype, supporting this hypothesis.…”
Objective:Psychosis -a complex and heterogeneous neuropsychiatric condition characterized by hallucinations and delusions -is a common feature of schizophrenia. There is evidence for altered DNA methylation (DNAm) associated with schizophrenia in both brain and peripheral tissues. We aimed to undertake a systematic analysis of variable DNAm associated with psychosis, schizophrenia, and treatmentresistant schizophrenia, also exploring measures of biological ageing, smoking, and blood cell composition derived from DNAm data to identify molecular biomarkers of disease.
Methods:We quantified DNAm across the genome in blood samples from 4,483 participants from seven casecontrol cohorts including patients with schizophrenia or first-episode psychosis. Measures of biological age, cellular composition and smoking status were derived from DNAm data using established algorithms. DNAm and derived measures were analyzed within each cohort and the results combined by meta-analysis.
Results:Psychosis cases were characterized by significant differences in measures of blood cell proportions and elevated smoking exposure derived from the DNAm data, with the largest differences seen in treatment-resistant schizophrenia patients. DNAm at 95 CpG sites was significantly different between psychosis cases and controls, with 1,048 differentially methylated positions (DMPs) identified between schizophrenia cases and controls. Schizophrenia-associated DMPs colocalize to regions identified in genetic association studies, with genes annotated to these sites enriched for pathways relevant to disease. Finally, a number of the schizophrenia associated differences were only present in the treatment-resistant schizophrenia subgroup.
Conclusions:We show that DNAm data can be leveraged to derive measures of blood cell counts and smoking that are strongly associated with psychosis. Our DNAm meta-analysis identified multiple DMPs associated with both psychosis and a more refined diagnosis of schizophrenia, with evidence for differential methylation associated with treatment-resistant schizophrenia that potentially reflects exposure to clozapine.
“…Of note, because we can only derive proportion of cell types from whole blood DNA methylation data, and not actual counts, an increase in one or more cell types must be balanced by a decrease in one or more other cell types and an apparrent change in the proportion of one specific cell type does not mean that the actual abundance of that cell type is altered. Despite this, the results from DNA methylation-derived cell proportions are consistent with previous studies based on empirical cell abundance measures which have reported increased monocyte counts 67,68 , increased neutrophil counts 69,70 , increased monocyte to lymphocyte ratio 71,72 and increased neutrophil to lymphocyte ratio 71,73 in both schizophrenia and FEP patients compared to controls. Studies have also shown that higher neutrophil counts in schizophrenia patients correlate with a greater burden of positive symptoms 69 suggesting that variations in the number of neutrophils is a potential marker of disease severity 72 .…”
Section: Discussionsupporting
confidence: 88%
“…Despite this, the results from DNA methylation-derived cell proportions are consistent with previous studies based on empirical cell abundance measures which have reported increased monocyte counts 67,68 , increased neutrophil counts 69,70 , increased monocyte to lymphocyte ratio 71,72 and increased neutrophil to lymphocyte ratio 71,73 in both schizophrenia and FEP patients compared to controls. Studies have also shown that higher neutrophil counts in schizophrenia patients correlate with a greater burden of positive symptoms 69 suggesting that variations in the number of neutrophils is a potential marker of disease severity 72 . Our sub-analysis of treatment-resistant schizophrenia, which is associated with a higher number of positive symptoms 65 , found that the increase in granulocytes was primary driven by those with the more severe phenotype, supporting this hypothesis.…”
Objective:Psychosis -a complex and heterogeneous neuropsychiatric condition characterized by hallucinations and delusions -is a common feature of schizophrenia. There is evidence for altered DNA methylation (DNAm) associated with schizophrenia in both brain and peripheral tissues. We aimed to undertake a systematic analysis of variable DNAm associated with psychosis, schizophrenia, and treatmentresistant schizophrenia, also exploring measures of biological ageing, smoking, and blood cell composition derived from DNAm data to identify molecular biomarkers of disease.
Methods:We quantified DNAm across the genome in blood samples from 4,483 participants from seven casecontrol cohorts including patients with schizophrenia or first-episode psychosis. Measures of biological age, cellular composition and smoking status were derived from DNAm data using established algorithms. DNAm and derived measures were analyzed within each cohort and the results combined by meta-analysis.
Results:Psychosis cases were characterized by significant differences in measures of blood cell proportions and elevated smoking exposure derived from the DNAm data, with the largest differences seen in treatment-resistant schizophrenia patients. DNAm at 95 CpG sites was significantly different between psychosis cases and controls, with 1,048 differentially methylated positions (DMPs) identified between schizophrenia cases and controls. Schizophrenia-associated DMPs colocalize to regions identified in genetic association studies, with genes annotated to these sites enriched for pathways relevant to disease. Finally, a number of the schizophrenia associated differences were only present in the treatment-resistant schizophrenia subgroup.
Conclusions:We show that DNAm data can be leveraged to derive measures of blood cell counts and smoking that are strongly associated with psychosis. Our DNAm meta-analysis identified multiple DMPs associated with both psychosis and a more refined diagnosis of schizophrenia, with evidence for differential methylation associated with treatment-resistant schizophrenia that potentially reflects exposure to clozapine.
“…A recent cross-sectional study combined magnetic resonance imaging of the brain and differential blood analyses and observed significantly increased neutrophil granulocytes in FEP patients ( n = 137) vs controls ( n = 81). 9 Neutrophil granulocytes were associated with reduced total brain gray matter. Their counts correlated with clinical symptom severity, namely total, positive and general Positive and Negative Syndrome Scale (PANSS) subscores, but not with PANSS negative scores.…”
Innate immunity has been linked to initiation of Alzheimer’s disease and multiple sclerosis. Moreover, risk of first-episode psychosis (FEP) and schizophrenia (Sz) is increased after various infections in predisposed individuals. Thus, we hypothesized an analogous role of innate immunity with increased C-reactive protein (CRP) in non-affective psychosis. Differential blood count, CRP, neutrophil and monocyte–macrophage activation markers, cortisol and psychotic symptoms (Positive and Negative Syndrome Scale [PANSS]) were assessed in controls (n = 294) and acutely ill unmedicated FEP (n = 129) and Sz (n = 124) patients at baseline and after 6 weeks treatment. Neutrophils, monocytes, and CRP were increased in patients vs controls at baseline (P < .001), and neutrophil and monocyte counts correlated positively with activation markers. Eosinophils were lower at baseline in FEP (P < .001) and Sz (P = .021) vs controls. Differences in neutrophils (P = .023), eosinophils (P < .001), and CRP (P < .001) were also present when controlling for smoking and cortisol, and partially remitted after antipsychotic treatment. FEP patients with high neutrophils (P = .048) or monocytes (P = .021) had higher PANSS-P scores at baseline but similar disease course. CRP correlated with PANSS-P at baseline (ρ = 0.204, P = .012). Improvement of positive symptoms after treatment correlated with declining neutrophils (ρ = 0.186, P = .015) or CRP (ρ = 0.237, P = .002) and rising eosinophils (ρ = −0.161, P = .036). In FEP, normalization of neutrophils (ρ = −0.231, P = .029) and eosinophils (ρ = 0.209, P = .048) correlated with drug dosage. In conclusion, innate immune system activation correlated with PANSS-P, supporting the immune hypothesis of psychosis. Neutrophil and monocyte counts and CRP levels may be useful markers of disease acuity, severity, and treatment response.
“…The probable mechanism of the observed changes in psychosis may be associated with inflammatory disorders, dysregulation of the immune system [3,10], neurodevelopmental disorders, including genetic abnormalities, i.e., 22q11.2 (22q11DS) deletion [11,12], or neutrophil functioning in the severe forms of mental disorders [10]. Their higher levels strongly correlate with positive clinical symptoms, constituting a promising marker of disease progression [13]. In turn, the mentioned genetic disorders (22q11DS) are the cause of the limited growth of axons and dendrites, which impair the integrity of mitochondria and functioning of synapses in productive neurons [11].…”
Schizophrenia is a neurodevelopmental disorder featuring chronic, complex neuropsychiatric features. The etiology and pathogenesis of schizophrenia are not fully understood. Oxidative-antioxidant imbalance is a potential determinant of schizophrenia. Oxidative, nitrosative, or sulfuric damage to enzymes of glycolysis and tricarboxylic acid cycle, as well as calcium transport and ATP biosynthesis might cause impaired bioenergetics function in the brain. This could explain the initial symptoms, such as the first psychotic episode and mild cognitive impairment. Another concept of the etiopathogenesis of schizophrenia is associated with impaired glucose metabolism and insulin resistance with the activation of the mTOR mitochondrial pathway, which may contribute to impaired neuronal development. Consequently, cognitive processes requiring ATP are compromised and dysfunctions in synaptic transmission lead to neuronal death, preceding changes in key brain areas. This review summarizes the role and mutual interactions of oxidative damage and impaired glucose metabolism as key factors affecting metabolic complications in schizophrenia. These observations may be a premise for novel potential therapeutic targets that will delay not only the onset of first symptoms but also the progression of schizophrenia and its complications.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.